Medication Considerations

Medication evidence reviewed: September 27, 2026.

If medication is helping you stay well, changing it deserves careful thought. Earlier Entheo material recommended tapering antidepressants before a journey. That was too broad. A reduced psychedelic effect and a dangerous drug interaction are different questions, and stopping medication can create risks of its own.

Do not abruptly stop an SSRI or another psychiatric medication to prepare for a psychedelic experience. Taking an antidepressant does not automatically mean you need to taper. Continuing, changing or tapering a medication is an individual decision with the prescribing clinician, taking into account the particular medication, psychedelic and your current health. Never increase a psychedelic dose to overcome suspected medication-related blunting.

For some people, continuing an SSRI may be a reasonable option after an individual review. Most studies are small, use selected participants and monitoring, and cannot reliably detect rare harms or predict an individual experience. Tap et al., 2025 — scoping review; NNDC, 2025 — consensus statement.

Start with the substance

Psilocybin

Small monitored studies of psilocybin with an SSRI have not detected an increased serotonin-toxicity signal. In a short escitalopram trial, positive effects were largely preserved; an uncontrolled study of 19 people with depression who continued an SSRI reported improvement. Neither establishes safety for every person or proves that continuing and stopping work equally well. Becker et al., 2022 — psilocybin and escitalopram trial, Goodwin et al., 2023 — psilocybin with a continuing SSRI.

Retrospective reports often describe weaker mushroom effects during SSRI or SNRI use. A prospective naturalistic study also found reduced aspects of the experience, but similar reported improvements in mood and wellbeing. Self-selection, uncertain substances and other differences make these findings less conclusive than randomized comparisons. Neither intensity nor a quieter experience tells us reliably how much therapeutic benefit someone will receive. Gukasyan et al., 2023 — retrospective mushroom survey, Barbut Siva et al., 2024 — prospective naturalistic study.

LSD

A controlled study in 23 healthy adults found that LSD after six weeks of paroxetine preserved pleasant effects and reduced some unpleasant effects, while increasing LSD blood exposure. This is evidence about one combination under monitoring, not all SSRIs or treatment outcomes in people with depression. Becker et al., 2025 — LSD and paroxetine trial.

Older reports described blunting with SSRIs and stronger effects with tricyclic antidepressants. Those small, older observations do not establish a predictable response across medications. Halman et al., 2024 — systematic interaction review.

MDMA

MDMA is different from psilocybin and LSD. Controlled studies with paroxetine (an SSRI) and duloxetine (an SNRI) found reduced subjective effects, even though MDMA exposure increased. Feeling less does not mean there is less drug in the body or that taking more is safe. These studies do not establish whether continuing an antidepressant preserves MDMA-assisted therapy outcomes. Farré et al., 2007 — MDMA and paroxetine trial, Hysek et al., 2012 — MDMA and duloxetine trial.

MDMA with an MAOI can cause life-threatening toxicity; fatal cases with moclobemide have been reported. Do not combine them. This is not evidence that an SSRI with psilocybin carries the same risk. Pilgrim et al., 2012 — fatal MDMA–moclobemide interactions.

Observational findings are mixed. Adverse-event reports have raised concerns about some antidepressant combinations. A 2026 death-record study did not find higher odds associated with antidepressant prescribing when MDMA-related deaths were compared with other drug-related deaths. Neither design can establish the risk for a living person taking the combination, or show that antidepressants are protective. Cohen et al., 2021 — MDMA adverse-event reports, Rock et al., 2026 — MDMA/antidepressant death-record study.

Ayahuasca, DMT and 5-MeO-DMT

Ayahuasca contains MAO-inhibiting compounds as well as DMT. It should not be treated like psilocybin when reviewing antidepressants. Published reports raise serotonin-toxicity concerns with ayahuasca and serotonergic medication, and serious reactions with 5-MeO-DMT plus MAOIs. DMT alone, ayahuasca and 5-MeO-DMT are not interchangeable. Evidence on medication combinations remains limited; specialist review is needed. Halman et al., 2024 — systematic interaction review, Tap et al., 2025 — antidepressants and classic psychedelics scoping review.

Mescaline, peyote, ketamine and ibogaine

Modern evidence on mescaline–antidepressant combinations is sparse. Peyote contains mescaline; psilocybin findings cannot fill that evidence gap. Halman et al., 2024 — systematic interaction review.

Ketamine and esketamine have different pharmacology. Prescribed esketamine can be used with an oral antidepressant in appropriate clinical care; its labeling calls for attention to sedation with depressants and blood pressure with stimulants or MAOIs. This does not establish safety for unsupervised ketamine combinations. DailyMed — esketamine prescribing information.

Ibogaine has a distinct cardiac-risk profile, including QT prolongation—a change in the heart’s electrical recovery. It needs specialist assessment of cardiac health and interacting medicines, not an SSRI rule borrowed from psilocybin. American Journal of Psychiatry — potential harms and ibogaine cardiac risk.

01

Psilocybin + selected SSRIs

Small monitored studies are reassuring, but cannot establish safety for everyone.

02

LSD + paroxetine

A controlled study found preserved pleasant effects alongside higher blood exposure.

03

MDMA + antidepressants

Some combinations blunt effects despite higher exposure. MDMA with MAOIs can be life-threatening.

Look at the whole medication list

Bring prescriptions, occasional medicines, supplements and non-prescribed substances to the review. Include recent starts, reductions and stops. A medication name alone is not enough: why you take it, how stable you are and what else you take matter.

• SSRIs and SNRIs: Evidence for particular SSRIs is growing, but it does not establish the same result for every drug. Direct psilocybin safety evidence for SNRIs is thinner. Duloxetine’s MDMA findings should not be transferred to psilocybin. Tap et al., 2025 — antidepressants and classic psychedelics scoping review, Hysek et al., 2012 — MDMA and duloxetine trial.
• MAOIs: These require particular caution, especially with MDMA and other serotonin-releasing substances. A pharmacist should also check medicines with MAO-inhibiting activity, including linezolid and methylene blue. FDA, July 2026 — psychedelic clinical investigation guidance, Medsafe — other medicines associated with serotonin toxicity.
• Lithium: Lithium with classic psychedelics has a concerning seizure signal in published online reports. These reports cannot tell us how often it happens, but they warrant avoiding the combination and seeking specialist assessment—not stopping lithium to make a journey possible. Nayak et al., 2021 — lithium and classic psychedelic reports.
• Tricyclic antidepressants: Older LSD reports suggest potentiation. The limited evidence does not justify a class-wide “safe” label or a standard washout instruction. FDA, July 2026 — psychedelic clinical investigation guidance.
• Antipsychotics: Some, such as risperidone, can reduce classic psychedelic effects. This is not a reason to stop them or use them as a do-it-yourself rescue drug. The condition they treat may itself make a psychedelic experience inadvisable. Halman et al., 2024 — systematic interaction review, Johnson et al., 2008 — human hallucinogen safety guidelines.
• Benzodiazepines: Clinicians sometimes use these to manage severe distress in monitored settings. That is different from a sitter choosing a rescue medicine. Abrupt withdrawal can cause serious reactions, including seizures. Johnson et al., 2008 — human hallucinogen safety guidelines, FDA — benzodiazepine withdrawal warning.
• Stimulants: A controlled MDMA–methylphenidate study found greater cardiovascular and adverse effects without greater psychedelic effects. Do not generalize this finding into a quantified risk for every stimulant–psychedelic pair. Hysek et al., 2014 — MDMA and methylphenidate trial.
• Other mood stabilizers: Evidence for lamotrigine, valproate and carbamazepine combinations is inadequate to reassure readers. They are not interchangeable with lithium; the underlying bipolar or seizure disorder also needs assessment. Halman et al., 2024 — systematic interaction review, Sarparast et al., 2022 — systematic MDMA/psilocybin interaction review.
• Other antidepressants and anxiety medicines: Bupropion increased and prolonged some MDMA effects in a controlled study. Sparse data for trazodone, mirtazapine and buspirone do not make them reliable substitutes or home “trip stoppers.” Schmid et al., 2015 — MDMA and bupropion trial, Sarparast et al., 2022 — systematic MDMA/psilocybin interaction review.

Pain and cough medicines matter too. Tramadol, pethidine and dextromethorphan have recognized serotonin-toxicity interactions with serotonergic antidepressants; fentanyl and methadone also merit review. That evidence concerns those drug combinations, not a measured risk for every psychedelic combination. Medsafe, 2022 — opioids and serotonergic medicines.

Also list migraine medicines such as triptans, antihistamines, Parkinson’s medicines, antibiotics, cancer treatments and supplements such as St John’s wort, 5-HTP or tryptophan. Entheo’s old chart grouped many of these under “serotonergic drugs.” It was not a tested psychedelic-interaction chart. We have removed it: a shared serotonin label cannot tell you how two particular drugs will interact.

What about serotonin syndrome?

Serotonin toxicity is a potentially serious drug reaction. Confusion or agitation with overheating and marked muscle stiffness or repeated involuntary jerking needs urgent medical assessment. Seizures, collapse or trouble breathing are emergencies. Call emergency services and tell responders what was taken; do not assume this is simply a difficult journey. Medsafe, 2022 — opioids and serotonergic medicines.

The small psilocybin–SSRI studies are reassuring within their limits. They cannot rule out a rare event, higher-risk combinations or risks in people excluded from trials. MDMA–MAOI fatalities should not be used as proof that an SSRI–psilocybin combination has the same risk. Goodwin et al., 2023 — psilocybin with a continuing SSRI, Pilgrim et al., 2012 — fatal MDMA–moclobemide interactions.

Changing medication has its own costs

Stopping an effective antidepressant is not a neutral step. Withdrawal can include dizziness, nausea, electric-shock sensations, sleep problems and anxiety; it can be severe or prolonged. Depression or anxiety can also return or worsen. Withdrawal and recurrence can overlap, so symptoms need assessment rather than a guess. NICE NG222 — stopping antidepressant medication, Royal College of Psychiatrists — stopping antidepressants.

In the ANTLER randomized trial, people assigned to discontinue maintenance antidepressants had more depression relapse over a year than those assigned to continue. This was not a psychedelic study, and its results are not an individual prediction. It does show why stopping an effective treatment deserves attention in its own right. Lewis et al., 2021 — ANTLER maintenance/discontinuation trial.

Tapering may still be considered for some people. It should follow an individual discussion with the prescribing clinician, with monitoring and a plan if symptoms worsen—not a deadline set by a journey, retreat or guidebook. For some people, avoiding destabilization matters more than seeking a stronger psychedelic effect.

A practical way to decide

1. Start with your reason. What are you hoping will change? What other options could help? A psychedelic experience is optional.
2. Look at stability. Review mood, sleep, recent crises and medication changes. Bipolar disorder, psychosis vulnerability, significant suicidality, seizures, clinical instability or serious medical illness call for appropriate professional assessment. A checklist cannot clear someone to proceed. Johnson et al., 2008 — human hallucinogen safety guidelines, NNDC task group, 2025 — clinical consensus statement.
3. Review the actual combination. Ask about both physical risks and altered effects, including what has not been studied.
4. Compare the choices. Continuing, clinician-supported tapering, postponing and not proceeding each have trade-offs. A medication change is not proof that a journey is appropriate.
5. Make a support plan. Decide who will monitor changes, who to contact if things worsen and what support is available afterward.

Questions to bring to your prescriber

• How much is this medication helping me, and what happened during previous changes?
• What is known about my exact medication and this particular substance?
• Are we concerned about toxicity, a quieter experience, my underlying condition, or all three?
• Would changing an effective medication be worth the uncertain benefit?
• If you do not work with psychedelics, could a clinical pharmacist or specialist help review the evidence?
• If we consider a change, who will follow me and what is our plan if I become unwell?

If you have already started tapering or recently stopped

Contact your prescriber with what changed, when it changed and any new symptoms. Do not rush further changes to meet a planned journey date, or make restart decisions from this page. Pause the psychedelic plan while symptoms and stability are assessed. Seek urgent help for suicidal thoughts, mania, psychosis or an inability to stay safe. Royal College of Psychiatrists — stopping antidepressants.

The point to remember

An SSRI does not automatically need to be stopped, and staying on one does not automatically make a combination safe. Protect your stability, review the specific combination, and never take more psychedelic to push through a blunted effect.

Continue with our SSRI article, medical screening and the Preparation Guidebook.